Abstract:Real-time monitoring of the biological behavior of extracellular vesicles (EVs) in vivo is limited, which hinders its application in biomedicine and clinical translation. A noninvasive imaging strategy could provide us with useful information on EVs' distribution, accumulation and homing in vivo, and pharmacokinetics. In this study, the long half-life radionuclide iodine-124 (124I) was used to directly label umbilical cord mesenchymal stem cell-derived EVs. The resulting probe, namely, 124I-MSC-EVs, was manufactured and ready to use within 1 min. 124I-labeled MSC-EVs had high radiochemical purity (RCP, >99.4%) and stable in 5% human serum album (HSA) with RCP > 95% for 96 h. We demonstrated efficient intracellular internalization of 124I-MSC-EVs in two prostate cancer cell lines (22RV1 and DU145 cell). The uptake rates of 124I-MSC-EVs in human prostate cancer cell lines 22RV1 and DU145 cells were 10.35 ± 0.78 and 2.56 ± 0.21 (AD%) at 4 h. The promising cellular data has prompted us to investigate the biodistribution and in vivo tracking capability of this isotope-based labeling technique in tumor bearing animals. Using positron emission tomography (PET) technology, we showed that the signal from intravenously injected 124I-MSC-EVs mainly accumulated in the heart, liver, spleen, lung, and kidney in healthy kun ming (KM) mice, and the biodistribution study was similar to the imaging results. In the 22RV1 xenograft model, 124I-MSC-EVs accumulated significantly in the tumor after administration, and with the optimal image acquired at 48 h postinjection, the maximum of standard uptake value (SUVmax) of the tumor was 3-fold higher than that of DU145. Taken together, the probe has a high application prospect in immuno-PET imaging of EVs. Our technique provides a powerful and convenient tool for understanding the biological behavior and pharmacokinetic characteristics of EVs in vivo and facilitates the acquirement of comprehensive and objective data for future clinical studies of EVs.

In Vivo Imaging for the Visualization of Extracellular Vesicle‐Based Tumor Therapy

Research progress in in vivo tracing technology for extracellular vesicles

Molecular imaging-guided extracellular vesicle-based drug delivery for precise cancer management: Current status and future perspectives

The Role of Extracellular Vesicles in Tumor Therapy and Imaging

Unveiling Invisible Extracellular Vesicles: Cutting-Edge Technologies for Their in Vivo Visualization

An Update on in Vivo Imaging of Extracellular Vesicles as Drug Delivery Vehicles

Current Perspectives on In Vivo Noninvasive Tracking of Extracellular Vesicles with Molecular Imaging

Theranostic extracellular vesicles: a concise review of current imaging technologies and labeling strategies

Emerging strategies for labeling and tracking of extracellular vesicles

In Vivo Visualized Tracking of Tumor-Derived Extracellular Vesicles Using CRISPR-Cas9 System.

Extracellular Vesicles (evs) in Tumor Diagnosis and Therapy

One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals

Extracellular vesicles as drug vectors for precise cancer treatment.

The power of imaging to understand extracellular vesicle biology in vivo

Advances in Extracellular Vesicle Nanotechnology for Precision Theranostics

Imaging extracellular vesicles: current and emerging methods

Extracellular vesicles: Emerging tools as therapeutic agent carriers

Advances and challenges in clinical applications of tumor cell-derived extracellular vesicles

Application of engineered extracellular vesicles for targeted tumor therapy

Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges

Selection of Fluorescent, Bioluminescent, and Radioactive Tracers to Accurately Reflect Extracellular Vesicle Biodistribution in Vivo